A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Arms (2)

1. type

   EXPERIMENTAL

   label

   1

   interventionNames

   1. Drug: bevacizumab [Avastin]
   2. Drug: 5 FU
   3. Drug: Streptozotocin

2. type

   EXPERIMENTAL

   label

   2

   interventionNames

   1. Drug: bevacizumab [Avastin]
   2. Drug: Xeloda

Primary outcomes (3)

1. measure

   Progression-Free Survival (PFS) - Percentage of Participants With an Event

   timeFrame

   Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

   description

   PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.